Anti-PD-1–GITR-L-treatment also showed prolonged overall survival for CT26, EMT6 and JC tumor-bearing mice (~70% of mice were tumor free for >50 days; Extended Data Fig. 6h–j). This evidence concerns the gene TNFRSF18 and neoplasm.